Liver Cancer (May 2020)

Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma

  • Susumu Maruta,
  • Sadahisa Ogasawara,
  • Yoshihiko Ooka,
  • Masamichi Obu,
  • Masanori Inoue,
  • Norio Itokawa,
  • Yuki Haga,
  • Atsuyoshi Seki,
  • Shinichiro Okabe,
  • Ryosaku Azemoto,
  • Ei Itobayashi,
  • Masanori Atsukawa,
  • Nobuyuki Sugiura,
  • Hideaki Mizumoto,
  • Keisuke Koroki,
  • Kengo Kanayama,
  • Hiroaki Kanzaki,
  • Kazufumi Kobayashi,
  • Soichiro Kiyono,
  • Masato Nakamura,
  • Naoya Kanogawa,
  • Tomoko Saito,
  • Takayuki Kondo,
  • Eiichiro Suzuki,
  • Shingo Nakamoto,
  • Akinobu Tawada,
  • Tetsuhiro Chiba,
  • Makoto Arai,
  • Tatsuo Kanda,
  • Hitoshi Maruyama,
  • Naoya Kato

DOI
https://doi.org/10.1159/000507022

Abstract

Read online

Background: The present study aimed to assess the efficacy and safety of lenvatinib and verify the possibility of lenvatinib for the expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma (HCC) in real-world practice, primarily focusing on the population that was excluded in the REFLECT trial. Methods: We retrospectively collected data on patients with advanced HCC who were administered lenvatinib in 7 institutions in Japan. Results: Of 152 advanced HCC patients, 95 and 57 patients received lenvatinib in first-line and second- or later-line systemic therapies, respectively. The median progression-free survival in Child-Pugh class A patients was nearly equal between first- and second- or later-line therapies (5.2 months; 95% CI 3.7–6.9 for first line, 4.8 months; 95% CI 3.8–5.9 for second or later line, p = 0.933). According to the modified Response Evaluation Criteria in Solid Tumors, the objective response rate of 27 patients (18%) who showed a high burden of intrahepatic lesions (i.e., main portal vein and/or bile duct invasion or 50% or higher liver occupation) at baseline radiological assessment was 41% and similar with that of other population. The present study included 20 patients (13%) with Child-Pugh class B. These patients observed high frequency rates of liver function-related adverse events due to lenvatinib. The 8-week dose intensity of lenvatinib had a strong correlation with liver function according to both the Child-Pugh and albumin – bilirubin scores. Conclusion: Lenvatinib had potential benefits for patients with advanced HCC with second- or later-line therapies and a high burden of intrahepatic lesions. Dose modification should be paid increased attention among patients with poor liver function, such as Child-Pugh class B patients.

Keywords